<DOC>
	<DOCNO>NCT02900664</DOCNO>
	<brief_summary>The purpose study combine PDR001 checkpoint inhibitor four agent immunomodulatory activity identify dos schedule combination therapy preliminarily assess safety , tolerability , pharmacological clinical activity combination .</brief_summary>
	<brief_title>A Study PDR001 Combination With CJM112 , EGF816 , Ilaris® ( Canakinumab ) Mekinist® ( Trametinib )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients advanced/metastatic cancer , measurable disease determine RECIST version 1.1 , progress despite standard therapy intolerant standard therapy , effective therapy available . Patients must fit one follow group : Colorectal cancer ( CRC ) ( mismatch repair deficient local assay include PCR and/or immunohistochemistry ) Nonsmall cell lung cancer ( NSCLC ) ( adenocarcinoma ) Triple Negative Breast Cancer ( TNBC ) ( D ECOG Performance Status ≤ 2 Patient must site disease amenable biopsy , candidate tumor biopsy accord treat institution 's guideline . Patient must willing undergo new tumor biopsy baseline , therapy study . Prior therapy PD1/PDL1 inhibitor allow provided toxicity attribute prior PD1 PDL1directed therapy lead discontinuation therapy . Written informed consent must obtain prior screen procedure procedure perform part standard care . Other protocoldefined inclusion criterion may apply . Presence symptomatic central nervous system ( CNS ) metastases , CNS metastases require local CNSdirected therapy , increase dos corticosteroid within prior 2 week . History severe hypersensitivity reaction monoclonal antibody . Out range laboratory value measure hepatic renal function , electrolytes blood count Impaired cardiac function clinically significant cardiac disease . Patients active , know suspected autoimmune disease . Human Immunodeficiency Virus infection screen . Escalation part : Active Hepatitis B ( HBV ) Hepatitis C ( HCV ) virus infection screen . Expansion part : Patients active HBV HCV exclude , except patient undergoing treatment HBV HCV . Malignant disease , treat study . Recent systemic anticancer therapy Active infection require systemic antibiotic therapy . Patients require chronic treatment systemic steroid therapy , replacement dose steroid set adrenal insufficiency . Patients receive systemic treatment immunosuppressive medication , except Use live vaccine infectious disease ( e.g . influenza , varicella , pneumococcus ) within 4 week initiation study treatment . Participation interventional , investigational study within 2 week first dose study treatment . Presence ≥ CTCAE grade 2 toxicity ( except alopecia ototoxicity , exclude ≥ CTCAE grade 3 ) due prior cancer therapy . Recent use hematopoietic colonystimulating growth factor ( e.g . GCSF , GMCSF , MCSF ) Additional exclusion criterion Combination arm PDR001+canakinumab Patients tuberculosis ( TB ) . Note : Patient latent TB may eligible base investigator 's benefitrisk assessment . Patients infected HBV HCV include inactive disease . Additional exclusion criterion Combination arm PDR001+CJM112 Patients TB . Note : Patient latent TB may eligible base investigator 's benefitrisk assessment . Patients history and/or active inflammatory bowel disease . Active skin soft tissue infection include cellulitis , erysipelas , impetigo , furuncle , carbuncle , abscess , fasciitis . Active candida infection , include mucocutaneous infection history invasive candidiasis . Additional exclusion criterion Combination arm PDR001+trametinib Patients history retinal vein oclusion . Patients history interstitial lung disease pneumonitis . Patients cardiomyopathy and/or LVEF &lt; LLN . Impairment gastrointestinal function GI disease may significantly alter absorption oral combination partner . Additional exclusion criterion Combination arm PDR001+EGF816 NSCLC patient EGFR mutant tumor . Strong inhibitor strong inducer CYP3A4 use concomitantly . Patients history interstitial lung disease . Patients infected HBV HCV include inactive disease . Impairment gastrointestinal function GI disease may significantly alter absorption oral combination partner Patients receive radiotherapy lung field within 6 month study treatment start . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CRC</keyword>
	<keyword>TNBC</keyword>
	<keyword>NSCLC ( adenocarcinoma )</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Bayesian logistic regression model</keyword>
	<keyword>PDR001</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>